Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262235 · ClinicalTrials.gov registry record · Phase 1
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1 study of Cancer and Neuroendocrine Tumors, sponsored by Arbutus Biopharma Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 8
- Study locations
NCT01262235 is a Phase 1 study of Cancer and Neuroendocrine Tumors that has completed, run by Arbutus Biopharma Corporation. The registered enrollment target is 68 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT01262235, a Phase 1 study of Cancer and Neuroendocrine Tumors, has completed, sponsored by Arbutus Biopharma Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid tumors or lymphomas that are refractory to standard therapy or for whom there is no standard therapy. After the determination of the maximum tolerated dose this dose will be utilized in an expansion cohort or subjects with refractory neuroendocrine tumors (NET) or adrenocortical carcinoma (ACC) tumors.
Conditions Studied
Interventions
- DRUG TKM-080301
Study Locations (8)
Arizona
- Scottsdale Healthcare Research Institute - Scottsdale
- Mayo Clinic Arizona - Scottsdale
Florida
- Moffitt Cancer Center - Tampa
Iowa
- University of Iowa/Holden Comprehensive Cancer Center - Iowa City
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Texas
- Westchase Oncology Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2010-12 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01262235
The ClinicalTrials.gov registry entry for NCT01262235 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Arbutus Biopharma Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which TKM-080301 is the first listed.
NCT01262235 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Arizona, Florida, Iowa.
Frequently Asked Questions
What is clinical trial NCT01262235 about?
NCT01262235 is a clinical study titled "A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients". This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid tumors or lymphomas that are refractory to standard therapy or for who...
What is the current status of trial NCT01262235?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2010-12. Estimated completion is 2015-08.
What conditions does trial NCT01262235 study?
This clinical trial studies the following conditions: Cancer, Neuroendocrine Tumors, Adrenocortical Carcinoma, ACC, NET.
What interventions are being tested in trial NCT01262235?
The interventions under investigation include: TKM-080301 (DRUG).
Who is sponsoring clinical trial NCT01262235?
This trial is sponsored by Arbutus Biopharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01262235 being conducted?
This trial has 8 study locations across Arizona, Florida, Iowa, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.